In a surprise move, the FDA rejected andexanet alfa (AndexXa), the antidote to anticoagulants like apixaban (Eliquis) and rivaroxaban (Xarelto). The agency had previously designated the drug as a Breakthrough Therapy — now, there is still no FDA-approved drug to reverse major bleeding with Factor Xa inhibitors.